Resting-state alterations in behavioral variant frontotemporal dementia are related to the distribution of monoamine and GABA neurotransmitter systems

Keyphrases

• Frontotemporal Dementia 100%
• Resting State 100%
• Monoamines 100%
• Neurotransmitter Systems 57%
• Functional Alterations 42%
• Fractional Amplitude of Low-frequency Fluctuation (fALFF) 42%
• Colocalization 28%
• MRNA Gene Expression 28%
• Norepinephrine Transporter 28%
• Selective Vulnerability 28%
• Spatial Distribution 14%
• Neurodegenerative Diseases 14%
• Disease Severity 14%
• Dementia Patients 14%
• Ministry of Education 14%
• Frontotemporal Lobar Degeneration 14%
• Cognitive Impairment 14%
• Healthy Controls 14%
• Clinical Symptoms 14%
• Frontotemporal 14%
• Structural Alterations 14%
• Data-driven Methods 14%
• Acid Type 14%
• Pharmacological Intervention 14%
• Aminobutyric Acid 14%
• Serotonin 14%
• Gene Expression Level 14%
• Non-pathogenic 14%
• Symptom Severity 14%
• Disease Mechanisms 14%
• Means of Control 14%
• Local Activity 14%
• Frontoparietal 14%
• Frontal Region 14%
• Resting-state Functional Magnetic Resonance Imaging (rs-fMRI) 14%
• GABAA Receptor (GABAAR) 14%
• Cognitive Symptoms 14%
• Clinical Change 14%
• Brain Functional Activity 14%
• Disease-related 14%
• Temporal Region 14%
• Activity Reduction 14%
• Serotonin 2A Receptor (5-HT2AR) 14%

Neuroscience

• Frontal Variant Frontotemporal Dementia 100%
• Monoamine 100%
• Gamma-Aminobutyric Acid 100%
• Neurotransmitter 57%
• Gene Expression 42%
• Norepinephrine Transporter 28%
• Messenger RNA 28%
• Neurodegenerative Disorder 14%
• Serotonin 14%
• Functional Magnetic Resonance Imaging 14%
• Receptor 14%

Pharmacology, Toxicology and Pharmaceutical Science

• 4 Aminobutyric Acid 100%
• Monoamine 100%
• Frontal Variant Frontotemporal Dementia 100%
• Neurotransmitter 57%
• Noradrenalin Transporter 28%
• Messenger RNA 28%
• Diseases 28%
• Receptor 14%
• Disease Severity 14%
• Degenerative Disease 14%
• Serotonin 14%